Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study.

Introduction: The safety and efficacy of low-molecular-weight heparin (LMWH) treatment in patients with cancer-associated thrombosis (CAT) beyond 6months are unknown. Our aim was to determine the safety of long-term tinzaparin use in patients with CAT.

Methods: We performed a prospective, open, single arm, multicentre study in patients with CAT receiving treatment with tinzaparin.